Peptides DB
Research-centric peptide and protocol reference hub
Study 12 of 29Pasireotide literaturebiorxiv-preprint · Observational2025

Hypothalamic deiodinase type-3 establishes the period of circannual interval timing in mammals

Dio3 expression is essential for establishing the period of circannual timing in Djungarian hamsters, but findings may not directly apply to humans.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the pasireotide corpus
1
Preclinical
20
Observational · this one
0
Open-label
3
Randomised
5
Reviews

Summary and findings

This study examined the role of deiodinase type-3 (Dio3) in circannual timing in Djungarian hamsters. The research involved transcriptomic sequencing and targeted mutation of Dio3 using CRISPR-Cas. Results indicated that Dio3 expression is crucial for establishing the period of circannual interval timing.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2025

Abstract

The authors’ words, as biorxiv-preprint supplied them

Animals respond to environmental cues to time phenological events, but the intrinsic mechanism of circannual timing remains elusive. We used transcriptomic sequencing and frequent sampling of multiple hypothalamic nuclei in Djungarian hamster to examine the neural and molecular architecture of circannual interval timing. Our study identified three distinct phases of transcript changes, with deiodinase type-3 ( Dio3 ) expression activated during the early induction phase. Subsequent work demonstrated that targeted mutation of Dio3 using CRISPR-Cas resulted in a shorter period for circannual interval timing. Hamsters that are non-responsive to short photoperiod and fail to show any winter adaptations do not display changes in Dio3 expression do not show any change in body mass or pelage. Our work demonstrates that changes in Dio3 induction is essential for setting the period of circannual interval timing.

Elsewhere in the Pasireotide corpus

BRecurrent Cushing's disease due to postoperative seeding of tumor cells in the sphenoid sinus: a case report with review of the literature.Endocrine journal · 2026 · n=1 · Not reported in abstract.HumanBPasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.Pituitary · 2026 · n=6 · Median follow-up of 3.3 years (range 0.5 to 5.9).HumanBPredictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.Journal of neuroendocrinology · 2023 · n=44 · No significant in vitro inhibition of cell proliferation was observed, ranging from -4.2% (OCT and PAS) to -7.4% (BIM-53097 + PAS).In vitroCPredictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.Journal of neuroendocrinology · 2026 · No significant in vitro inhibition of cell proliferation was observed, ranging from -4.2% (OCT and PAS) to -7.4% (BIM-53097 + PAS).In vitroBApproach to the patient: precision medicine-guided evaluation and treatment of acromegaly.The Journal of clinical endocrinology and metabolism · 2026 · 80% of patients achieved hormonal control with biomarker-guided treatment.reviewBTirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.Endocrine journal · 2026 · n=1 · HbA1c decreased from 7.7% to 6.3% after switching to tirzepatide.Human